Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc. reported an insider transaction involving its Chief Operating Officer, Anish Patel, through an associated family trust. On January 9, 2026, The Patel / Dong Family Trust, for which Patel serves as trustee, sold 48,057 shares of Enliven common stock at a weighted average price of $27.9842, and an additional 243 shares at $28.50.
The filing states these sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024, which is a pre-arranged plan for trading the issuer’s equity securities. After these transactions, the trust held 215,011 shares of Enliven common stock, all reported as indirectly owned.
Enliven Therapeutics, Inc. insider activity shows that a trust associated with Chief Scientific Officer Joseph P. Lyssikatos sold a total of 132,500 shares of common stock in early January 2026. The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee, reported sales of 7,500 shares at a weighted average price of $20.1282 on 01/08/2026, followed by 33,802 shares at $24.9238 on the same date. On 01/09/2026, the trust sold 41,198 shares at a weighted average price of $24.9008 and 50,000 shares at $29.1343. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024, and after the final sale, the trust beneficially owned 765,188 shares.
Enliven Therapeutics director Richard A. Heyman reported indirect sales of the company’s common stock through entities associated with him. On January 8, 2026, RAHD Capital LLC, for which he serves as a managing member, sold 1,620 shares at $25.00 per share under a Rule 10b5-1 trading plan adopted on November 15, 2024, and held 25,545 shares of Enliven common stock indirectly afterward.
Also on January 8, 2026, the Richard A. Heyman and Anne E. Daigle Trust sold 8,015 shares at a weighted average price of $25.035, and on January 9, 2026 sold a further 4,285 shares at $25.0001, both under a Rule 10b5-1 plan and held 29,392 shares indirectly afterward. In addition, Heyman is reported as directly beneficially owning 123,673 shares of Enliven common stock.
Enliven Therapeutics director Garland J. Scott reported a new stock option grant on a Form 4. On January 7, 2026, he was awarded a stock option to buy 59,372 shares of Enliven Therapeutics, Inc. common stock at an exercise price of $15.47 per share, expiring on January 7, 2036. The filing states that one‑thirty‑sixth of the shares subject to the option will vest on February 7, 2026 and then monthly thereafter, as long as he continues serving as an outside director on each vesting date. The option is reported as directly owned and was granted at a price of $0 for the derivative itself.
Enliven Therapeutics, Inc. director Garland J. Scott filed an initial ownership report showing holdings of fully vested stock options. As of January 7, 2026, he holds options to purchase 13,072 shares of common stock at an exercise price of $24.12 expiring on September 26, 2034, and options to purchase 13,508 shares at an exercise price of $22.47 expiring on February 6, 2035. The filing characterizes these positions as directly owned, and notes that all shares subject to these options are fully vested and exercisable as of the filing date.
Enliven Therapeutics insider Joseph Lyssikatos has filed a Form 144 notice to sell 75,000 common shares. The shares are to be sold through Jefferies LLC on Nasdaq, with an indicated aggregate market value of $1,743,750.00. The filing notes that there were 59,000,000 shares of this class outstanding.
The 75,000 shares were originally acquired as founder shares from Enliven Therapeutics on 09/01/2019. The form also lists recent sales by Lyssikatos over the past three months, including 12,500 shares on 10/20/2025, 12,500 on 11/19/2025, 5,000 on 12/19/2025, 41,302 on 01/08/2026, and 41,198 on 01/09/2026, each with disclosed gross proceeds. By signing, the seller represents they are not aware of any undisclosed material adverse information about the company.
Enliven Therapeutics insider plans to sell additional shares under Rule 144. A notice has been filed to sell 75,000 shares of Enliven Therapeutics common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,743,750 and 59,000,000 shares outstanding. The shares to be sold are founder shares originally acquired on September 1, 2019 from Enliven Therapeutics.
The filing also lists prior sales over the past three months by the same seller, including 12,500 Enliven Therapeutics securities sold on November 17, 2025 for $272,739.30 and 38,757 sold on January 8, 2026 for $930,261.95, plus an additional 43,743 sold on January 9, 2026 for $1,089,200.70.
Enliven Therapeutics insider Anish Patel has filed a notice to sell common stock under Rule 144. The filing covers 48,300 common shares to be sold through Jefferies LLC on or about 01/09/2026 on the Nasdaq market, with an aggregate market value of $1,122,975.00. The filing notes 59,000,000 shares of the issuer’s stock outstanding.
The shares to be sold are founder shares of common stock acquired from Enliven Therapeutics on 09/01/2019. Over the past three months, Patel has already sold 6,667 shares for gross proceeds of $116,034.33 on 11/07/2025 and 6,663 shares for gross proceeds of $140,072.92 on 12/08/2025. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Enliven Therapeutics insider plans a new stock sale under Rule 144. A Form 144 notice discloses an intention to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an approximate sale date of 01/08/2026. The filing lists an aggregate market value of $1,276,275.00 for these shares, against 59,000,000 common shares outstanding.
The 82,500 shares are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. Over the past three months, the same seller, Samuel Kintz, reported sales of Enliven Therapeutics stock: 12,500 shares on 10/17/2025 for $266,653.75, 12,500 shares on 11/17/2025 for $272,739.30, and 5,000 shares on 12/17/2025 for $81,892.60.
Enliven Therapeutics insider Joseph Lyssikatos has filed a Rule 144 notice to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,276,275.00. The filing notes that 59,000,000 shares of this class were outstanding and that the planned sale is expected around 01/08/2026.
The shares to be sold are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. Over the prior three months, Lyssikatos sold additional Enliven Therapeutics Inc shares in three transactions: 12,500 shares on 10/20/2025 for $276,024.53, 12,500 shares on 11/19/2025 for $279,155.45, and 5,000 shares on 12/19/2025 for $84,206.00.